Fast-acting insulin aspart (Fiasp®) improves glycemic outcomes when used with MiniMed670G hybrid closed-loop system in simulated trials compared to NovoLog®

Benyamin Grosman, Di Wu, Neha Parikh, Anirban Roy, Gayane Voskanyan, Natalie Kurtz, Jeppe Sturis, Ohad Cohen, Magnus Ekelund, Robert A. Vigersky

Abstract: Highlights•Faster insulin action is hypothesized to improve closed-loop system results with insulin dependent Diabetes.•We studied using Medtronic MiniMedTM novel simulation environment the benefits of switching between NovoLog® to Fiasp® insulin (Novo Nordisk A/S, Bagsværd, Denmark) with the MiniMedTM 670G system (Medtronic, Northridge, CA, USA).•The simulation studies were compared with clinical results.